4.6 Article

Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients

期刊

CANCERS
卷 14, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/cancers14082045

关键词

KRAS; colorectal cancer biomarkers; gene mutations; algorithm; colorectal cancer metastasis; colorectal cancer progression

类别

资金

  1. EU Targeted therapy for advanced colorectal cancer patients (REVERT) [848 098]
  2. Swedish Cancer Society [CAN-2017-381]
  3. Swedish Children Foundation [TJ2015-0097]
  4. H2020-MSCA-ITN-2018-European Commission [721297]
  5. Swedish National Research Council [2019-01318]
  6. STINT Institutional Grant [IG2013-5595]
  7. Malmo Cancer Foundation
  8. Kempe STF
  9. Umea University
  10. Medical Faculty Instruments Grants
  11. Norland fund for Cancer Forskning
  12. Insamlingstiftelsen
  13. Bioteknik medel
  14. Medical Faculty infrastructure Grants, Medical Faculty, Umea University, Kempestiftelserna
  15. UCMR
  16. Bio-Film Center, Malmo University
  17. Swedish Research Council [2019-01318] Funding Source: Swedish Research Council
  18. Vinnova [2019-01318] Funding Source: Vinnova
  19. Forte [2019-01318] Funding Source: Forte

向作者/读者索取更多资源

We developed a new biomarker model, the 7-Gene Algorithm, using machine learning and gene mutations to predict treatment response in patients with metastatic colorectal cancer (mCRC). The algorithm showed high accuracy in predicting treatment response and has important implications for improving personalized therapies.
Simple Summary Despite the high incidence and mortality of metastatic colorectal cancer (mCRC), there are no new biomarker tools available for predicting treatment response at diagnosis. We used machine learning using gene mutations from primary tumors of patients and developed a new biomarker model termed a 7-Gene Algorithm. We showed that this algorithm can be used as a biomarker classifier to predict treatment response with better precision than the current predictive factors. The 7-Gene Algorithm showed high accuracy to predict treatment response for patients suffering mCRC. The novel 7-Gene Algorithm can be further developed as a biomarker model for improvement of personalized therapies. Purpose: Despite the high mortality of metastatic colorectal cancer (mCRC), no new biomarker tools are available for predicting treatment response. We developed gene-mutation-based algorithms as a biomarker classifier to predict treatment response with better precision than the current predictive factors. Methods: Random forest machine learning (ML) was applied to identify the candidate algorithms using the MSK Cohort (n = 471) as a training set and validated in the TCGA Cohort (n = 221). Logistic regression, progression-free survival (PFS), and univariate/multivariate Cox proportional hazard analyses were performed and the performance of the candidate algorithms was compared with the established risk parameters. Results: A novel 7-Gene Algorithm based on mutation profiles of seven KRAS-associated genes was identified. The algorithm was able to distinguish non-progressed (responder) vs. progressed (non-responder) patients with AUC of 0.97 and had predictive power for PFS with a hazard ratio (HR) of 16.9 (p < 0.001) in the MSK cohort. The predictive power of this algorithm for PFS was more pronounced in mCRC (HR = 16.9, p < 0.001, n = 388). Similarly, in the TCGA validation cohort, the algorithm had AUC of 0.98 and a significant predictive power for PFS (p < 0.001). Conclusion: The novel 7-Gene Algorithm can be further developed as a biomarker model for prediction of treatment response in mCRC patients to improve personalized therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据